NM_000587.4:c.1561C>A

Variant summary

Our verdict is Likely benign. Variant got -3 ACMG points: 1P and 4B. PP5BS2

The NM_000587.4(C7):​c.1561C>A​(p.Arg521Ser) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00311 in 1,611,512 control chromosomes in the GnomAD database, including 16 homozygotes. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).

Frequency

Genomes: 𝑓 0.0025 ( 1 hom., cov: 32)
Exomes 𝑓: 0.0032 ( 15 hom. )

Consequence

C7
NM_000587.4 missense

Scores

7
7
5

Clinical Significance

Conflicting classifications of pathogenicity criteria provided, conflicting classifications P:12U:5

Conservation

PhyloP100: 0.470
Variant links:
Genes affected
C7 (HGNC:1346): (complement C7) This gene encodes a serum glycoprotein that forms a membrane attack complex together with complement components C5b, C6, C8, and C9 as part of the terminal complement pathway of the innate immune system. The protein encoded by this gene contains a cholesterol-dependent cytolysin/membrane attack complex/perforin-like (CDC/MACPF) domain and belongs to a large family of structurally related molecules that form pores involved in host immunity and bacterial pathogenesis. This protein initiates membrane attack complex formation by binding the C5b-C6 subcomplex and inserts into the phospholipid bilayer, serving as a membrane anchor. Mutations in this gene are associated with a rare disorder called C7 deficiency. [provided by RefSeq, Nov 2016]

Genome browser will be placed here

ACMG classification

Classification made for transcript

Verdict is Likely_benign. Variant got -3 ACMG points.

PP5
Variant 5-40959520-C-A is Pathogenic according to our data. Variant chr5-40959520-C-A is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 12105.We mark this variant Likely_pathogenic, oryginal submissions are: {Likely_pathogenic=2, Uncertain_significance=4, Pathogenic=6}. Variant chr5-40959520-C-A is described in UniProt as null. Variant chr5-40959520-C-A is described in Lovd as [Likely_pathogenic]. Variant chr5-40959520-C-A is described in Lovd as [Pathogenic].
BS2
High Homozygotes in GnomAdExome4 at 15 AR gene

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
C7NM_000587.4 linkc.1561C>A p.Arg521Ser missense_variant Exon 12 of 18 ENST00000313164.10 NP_000578.2 P10643Q05CI3

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
C7ENST00000313164.10 linkc.1561C>A p.Arg521Ser missense_variant Exon 12 of 18 1 NM_000587.4 ENSP00000322061.9 P10643

Frequencies

GnomAD3 genomes
AF:
0.00248
AC:
377
AN:
152088
Hom.:
1
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.000700
Gnomad AMI
AF:
0.00
Gnomad AMR
AF:
0.00151
Gnomad ASJ
AF:
0.000288
Gnomad EAS
AF:
0.00
Gnomad SAS
AF:
0.00249
Gnomad FIN
AF:
0.000944
Gnomad MID
AF:
0.00633
Gnomad NFE
AF:
0.00434
Gnomad OTH
AF:
0.00239
GnomAD3 exomes
AF:
0.00233
AC:
574
AN:
246854
Hom.:
1
AF XY:
0.00238
AC XY:
319
AN XY:
133880
show subpopulations
Gnomad AFR exome
AF:
0.000525
Gnomad AMR exome
AF:
0.00102
Gnomad ASJ exome
AF:
0.00
Gnomad EAS exome
AF:
0.00
Gnomad SAS exome
AF:
0.000891
Gnomad FIN exome
AF:
0.000606
Gnomad NFE exome
AF:
0.00421
Gnomad OTH exome
AF:
0.00334
GnomAD4 exome
AF:
0.00318
AC:
4640
AN:
1459306
Hom.:
15
Cov.:
31
AF XY:
0.00312
AC XY:
2266
AN XY:
725784
show subpopulations
Gnomad4 AFR exome
AF:
0.000299
Gnomad4 AMR exome
AF:
0.00137
Gnomad4 ASJ exome
AF:
0.0000383
Gnomad4 EAS exome
AF:
0.00
Gnomad4 SAS exome
AF:
0.00134
Gnomad4 FIN exome
AF:
0.00103
Gnomad4 NFE exome
AF:
0.00381
Gnomad4 OTH exome
AF:
0.00254
GnomAD4 genome
AF:
0.00248
AC:
378
AN:
152206
Hom.:
1
Cov.:
32
AF XY:
0.00238
AC XY:
177
AN XY:
74402
show subpopulations
Gnomad4 AFR
AF:
0.000698
Gnomad4 AMR
AF:
0.00150
Gnomad4 ASJ
AF:
0.000288
Gnomad4 EAS
AF:
0.00
Gnomad4 SAS
AF:
0.00270
Gnomad4 FIN
AF:
0.000944
Gnomad4 NFE
AF:
0.00434
Gnomad4 OTH
AF:
0.00237
Alfa
AF:
0.00372
Hom.:
3
Bravo
AF:
0.00220
TwinsUK
AF:
0.00485
AC:
18
ALSPAC
AF:
0.00519
AC:
20
ESP6500AA
AF:
0.00
AC:
0
ESP6500EA
AF:
0.00388
AC:
32
ExAC
AF:
0.00247
AC:
298
Asia WGS
AF:
0.00115
AC:
4
AN:
3478

ClinVar

Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:12Uncertain:5
Revision: criteria provided, conflicting classifications
LINK: link

Submissions by phenotype

Complement component 7 deficiency Pathogenic:9Uncertain:1
Jul 17, 2023
Victorian Clinical Genetics Services, Murdoch Childrens Research Institute
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0102 - Loss of function is a known mechanism of disease in this gene and is associated with C7 deficiency (MIM#610102). (I) 0106 - This gene is associated with autosomal recessive disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from arginine to serine. (I) 0251 - This variant is heterozygous. (I) 0304 - Variant is present in gnomAD (v2) <0.01 for a recessive condition (653 heterozygotes, 1 homozygote). (SP) 0309 - Multiple alternative amino acid changes at the same position have been observed in gnomAD (v2) (highest allele count: 32 heterozygotes, 0 homozygotes). (I) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0600 - Variant is located in the annotated thrombospondin type 1 domain (DECIPHER). (I) 0801 - This variant has strong previous evidence of pathogenicity in unrelated individuals. This variant has been reported as a VUS, but more commonly as likely pathogenic or pathogenic (ClinVar). It is known as the C7PD allele, and was observed in multiple heterozygous, compound heterozygous or homozygous individuals with a subtotal or total C7 deficiency. It was also found in a heterozygous individual with an infection of the central nervous system, who had an additional heterozygous variant (c.2381+2T>C) in the C6 gene (PMID: 17407100, PMID: 31440263, PMID: 33386334). (SP) 1002 - This variant has moderate functional evidence supporting abnormal protein function. This variant has been proven to result in protein mislocalization into the endoplasmic reticulum, with significantly reduced secretion (PMID: 17407100). (SP) 1208 - Inheritance information for this variant is not currently available in this individual. (I) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign -

Jun 01, 2006
OMIM
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: literature only

- -

Jan 03, 2018
Baylor Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This variant was determined to be pathogenic according to ACMG Guidelines, 2015 [PMID:25741868]. This variant has been previously reported as disease causing [PMID 8871666] This variant has been previously reported in patients with complement component 7 deficiency [PMID 8871666, 16771861] -

Apr 28, 2022
HudsonAlpha Institute for Biotechnology, HudsonAlpha Institute for Biotechnology
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: research

ACMG codes: PS3, PS4_supporting, PM2_supporting, PP1 -

Aug 28, 2023
Intergen, Intergen Genetics and Rare Diseases Diagnosis Center
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Nov 29, 2023
3billion
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The variant is observed at an extremely low frequency in the gnomAD v2.1.1 dataset (total allele frequency: 0.235%). Predicted Consequence/Location: The majority of the known disease-causing variants of this gene are variants expected to result in premature termination of the protein. Premature termination of the protein is a common disease-causing mechanism for this gene. In silico tool predictions suggest damaging effect of the variant on gene or gene product [3Cnet: 0.78 (>=0.6, sensitivity 0.72 and precision 0.9)]. Same nucleotide change resulting in same amino acid change has been previously reported as pathogenic/likely pathogenic with strong evidence (ClinVar ID: VCV000012105 /PMID: 8871666). Therefore, this variant is classified as Likely pathogenic according to the recommendation of ACMG/AMP guideline. -

Nov 02, 2023
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The C7 c.1561C>A; p.Arg521Ser variant (rs121964920) is reported in several individuals with C7 deficiency who also carried a truncating C7 variant (Barroso 2006, Sanges 2017). The variant is reported in the ClinVar database (Variation ID: 12105) and is found in the general population with an overall allele frequency of 0.2% (655/278,228 alleles, including 1 homozygote) in the Genome Aggregation Database (v2.1.1). Computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.399). Based on available information, this variant is classified as likely pathogenic. References: Barroso S et al. Molecular defects of the C7 gene in two patients with complement C7 deficiency. Immunology. 2006 Jun;118(2):257-60. Sanges S et al. Diagnosis of primary antibody and complement deficiencies in young adults after a first invasive bacterial infection. Clin Microbiol Infect. 2017 Aug;23(8):576.e1-576.e5. -

-
Neuberg Centre For Genomic Medicine, NCGM
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

The observed missense c.1561C>A p.Arg521Ser variant in C7 gene has been observed in individuals with complement component 7 C7 deficiency Fernie et al., 1996; Barroso et al., 2006; Rameix-Welti et al., 2007; Kuijpers et al., 2010. Experimental studies have shown that this missense change affects C7 function Rameix-Welti et al., 2007 The p.Arg521Ser variant is present with allele frequency of 0.2% in gnomAD Exomes. This variant has been submitted to the ClinVar database as Uncertain Significance/ Likely Pathogenic/ Pathogenic multiple submissions. Multiple lines of computational evidence Polyphen - Probably Damaging, SIFT - Damaging and MutationTaster - Disease causing predict a damaging effect on protein structure and function for this variant. The reference amino acid of p.Arg521Ser in C7 is predicted as conserved by GERP++ and PhyloP across 100 vertebrates. The amino acid Arg at position 521 is changed to a Ser changing protein sequence and it might alter its composition and physico-chemical properties. For these reasons, this variant has been classified as Pathogenic. In absence of another reportable variant in C7 gene, the molecular diagnosis is not confirmed. -

Feb 08, 2023
Department of Pathology and Laboratory Medicine, Sinai Health System
Significance: Likely pathogenic
Review Status: criteria provided, single submitter
Collection Method: research

- -

Apr 10, 2024
Fulgent Genetics, Fulgent Genetics
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

not provided Pathogenic:2Uncertain:2
Jan 13, 2025
GeneDx
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

Published functional studies demonstrate a loss of function of C7 due to the defective folding of the protein (PMID: 17407100); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Also known as R499S; This variant is associated with the following publications: (PMID: 28192236, 8871666, 31980526, 16771861, 17407100, 31440263, 31589614, 34573280, 34426522, 28368462, 35899558, 39081726, 39062917) -

Nov 03, 2021
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Oct 25, 2022
Labcorp Genetics (formerly Invitae), Labcorp
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

This sequence change replaces arginine, which is basic and polar, with serine, which is neutral and polar, at codon 521 of the C7 protein (p.Arg521Ser). This variant is present in population databases (rs121964920, gnomAD 0.4%), and has an allele count higher than expected for a pathogenic variant. This missense change has been observed in individual(s) with complement component 7 (C7) deficiency (PMID: 8871666, 16771861, 17407100, 19931914). This variant is also known as R499S. ClinVar contains an entry for this variant (Variation ID: 12105). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt C7 protein function. Experimental studies have shown that this missense change affects C7 function (PMID: 17407100). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -

Jun 02, 2017
Blueprint Genetics
Significance: Pathogenic
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

C7 and C6 deficiency, combined subtotal Pathogenic:1
Jun 01, 2006
OMIM
Significance: Pathogenic
Review Status: no assertion criteria provided
Collection Method: literature only

- -

C7-related disorder Uncertain:1
Sep 17, 2024
PreventionGenetics, part of Exact Sciences
Significance: Uncertain significance
Review Status: no assertion criteria provided
Collection Method: clinical testing

The C7 c.1561C>A variant is predicted to result in the amino acid substitution p.Arg521Ser. This variant is alternatively referred to as p.Arg499Ser using Legacy nomenclature or as allele C7SD. This variant has been reported in the homozygous state in two unrelated individuals with combined complement component 6- (C6D) and complement component 7- (C7D) deficiency (referred to as C7 exon 11 mutation, Fig. 2, Family 1, Subject II.1 and Fig. 3, Family 2, Subject I.1, Fernie et al. 1996. PubMed ID: 8871666). Of note, one of these individuals was also homozygous for a splicing variant in the C6 gene. It has been reported in the heterozygous state along with a second truncating variant in C7 in individual with complement deficiencies (Fig. 1, Barroso et al. 2006. PubMed ID: 16771861; Sanges et al. 2017. PubMed ID: 28192236). This variant has been reported in the heterozygous state in two siblings with C7D (Fig. 7, Family 6, Subjects II.1 and 11.2, Fernie et al. 1996. PubMed ID: 8871666), in individuals with terminal complement pathway deficiency (Table S1, Rosain et al. 2017. PubMed ID: 28368462; Table 3, El Sissy et al. 2019. PubMed ID: 31440263), and in an individual with a inborn error of immunity (Table 1, Grossi et al. 2021. PubMed ID: 34573280). However, this variant has also been reported in the heterozygous state in individuals without C7D and is a common homozygous finding in the Turkish population (Fig. 2-4, 6, and 7, Fernie et al. 1996. PubMed ID: 8871666; Table S1, Capalbo et al. 2019. PubMed ID: 31589614; Hou et al. 2020. PubMed ID: 31980526; Table S4, Kars. 2021. PubMed ID: 34426522). This variant is reported in 0.41% of alleles in individuals of European (Non-Finnish) descent in gnomAD including one homozygous finding. At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -

not specified Uncertain:1
Mar 04, 2025
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
Significance: Uncertain significance
Review Status: criteria provided, single submitter
Collection Method: clinical testing

- -

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
AlphaMissense
Pathogenic
0.98
BayesDel_addAF
Benign
-0.022
T
BayesDel_noAF
Pathogenic
0.20
CADD
Benign
20
DANN
Uncertain
1.0
DEOGEN2
Benign
0.30
T
Eigen
Uncertain
0.47
Eigen_PC
Uncertain
0.23
FATHMM_MKL
Benign
0.14
N
LIST_S2
Pathogenic
0.99
D
M_CAP
Uncertain
0.11
D
MetaRNN
Uncertain
0.58
D
MetaSVM
Uncertain
0.67
D
MutationAssessor
Pathogenic
5.0
H
PrimateAI
Benign
0.42
T
PROVEAN
Pathogenic
-5.6
D
REVEL
Uncertain
0.40
Sift
Pathogenic
0.0
D
Sift4G
Pathogenic
0.0
D
Polyphen
1.0
D
Vest4
0.96
MVP
0.72
MPC
0.14
ClinPred
0.15
T
GERP RS
4.3
Varity_R
0.98
gMVP
0.89

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

LitVar

Below is the list of publications found by LitVar. It may be empty.

Other links and lift over

dbSNP: rs121964920; hg19: chr5-40959622; API